Trials / Sponsors / GTx

GTx

Industry · 19 registered clinical trials.

Status	Trial	Phase	Started
Withdrawn	Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence Stress Urinary Incontinence	Phase 2	2018-06-28
Withdrawn	Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Inc Stress Urinary Incontinence	Phase 2	2018-05-28
Completed	Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence Stress Urinary Incontinence	Phase 2	2017-08-21
Withdrawn	Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean ER+ and AR+ Breast Cancer	Phase 2	2016-04-01
Completed	GTx-024 as a Treatment for Stress Urinary Incontinence in Women Stress Urinary Incontinence	Phase 2	2016-01-01
Completed	Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer ER+ and AR+ Breast Cancer	Phase 2	2015-08-01
Terminated	Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ Triple Negative Breast Cancer	Phase 2	2015-06-01
Terminated	Phase II Study of GTx024 in Women With Metastatic Breast Cancer Metastatic Breast Cancer	Phase 2	2013-04-01
Completed	Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer Prostate Cancer	Phase 2	2012-08-14
Terminated	GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer Prostate Cancer	Phase 2	2011-09-01
Terminated	Phase II, Dose Finding Study of GTx-758 Prostate Cancer	Phase 2	2011-08-01
Completed	Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum Muscle Wasting, Non-Small Cell Lung Cancer	Phase 3	2011-07-01
Completed	Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) Muscle Wasting, Non Small Cell Lung Cancer	Phase 3	2011-07-01
Terminated	Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer Prostate Cancer	Phase 2	2011-06-01
Withdrawn	Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences Risk of Bone Fracture Occurrences	Phase 3	2011-03-01
Completed	Study of GTx-024 on Muscle Wasting (Cachexia) Cancer. Cachexia	Phase 2	2007-05-01
Completed	Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia) Preneoplastic Conditions, Prostatic Intraepithelial Neoplasia	Phase 3	2005-01-01
Completed	Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therap Prostate Cancer, Osteoporosis, Fractures	Phase 3	2003-10-01
Completed	A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia ( Prostatic Intraepithelial Neoplasia	Phase 2	2001-04-01